Humanin: a potential peptide for neuroprotective therapy against Alzheimer's disease.
Niikura. Takako T
Key Findings
- Humanin is a 24‑amino‑acid peptide that blocks neuron death caused by Alzheimer’s‑related stressors in cell cultures
- Synthetic humanin works against multiple Alzheimer’s insults, including amyloid‑beta
- A more potent humanin derivative improves memory deficits in an Alzheimer’s mouse model
Practical Outcomes
- The findings are interesting for future drug development, but there’s no safe dosage or protocol for humans yet. Biohackers should wait for clinical trials before trying any humanin‑based supplement or therapy.
Summary
Researchers found a tiny protein called humanin that can protect brain cells from the damage that causes Alzheimer’s, and a stronger version helped mice with the disease remember better, but this work is still in early lab and animal stages, not ready for everyday use.
Abstract
Neuronal cell death is a pathologic hallmark of Alzheimer's disease (AD), a devastating neurodegenerative disorder. To understand the cytotoxic mechanism underlying AD pathogenesis, a functional screen termed the 'disease-based death trap' has been used. This method was developed to identify antagonistic genes against neuronal cell death caused by an AD-associated insult. Among several antagonistic genes obtained, a cDNA was found that encodes a novel 24-residue peptide, which was later designated humanin (HN). The synthetic HN peptide suppresses neuronal cell death induced by all AD-related insults so far examined, including amyloid β in vitro. A highly potent HN derivative ameliorates amnesia in an AD mouse model, suggesting that therapy involving HN effectively targets neuronal death in AD.
Study Information
pubmed
2007
2007-08-29T00:00:00.000Z
10.1517/17460441.2.9.1273
5
77